AI brief of an SEC Form 8-K · Alnylam Pharmaceuticals (ALNY)

Alnylam grants CEO Greenstreet $18.0 million performance-based special equity award

Neutral Impact 3 of 5 leadership Written later

Alnylam's Board granted CEO Yvonne Greenstreet a special performance share award effective March 2, 2026, with a target of 55,373 shares and a stated face value of $18.0 million. The award pays out only if the stock's future 30-day average price reaches thresholds starting at $500 and reaching $800 by December 31, 2029, so it creates no value unless shareholders see significant stock price gains.

Key points

  • Target award: 55,373 performance share units, face value $18.0 million based on the $325.07 closing price on the Grant Date
  • Vesting range: 50% to 200% of target, tied to future average stock price thresholds of $500, $600, $700 and $800
  • Baseline threshold of $500 must be met or the award is forfeited in full; vesting date is December 31, 2029
  • The award was granted concurrently with the March 2, 2026 annual equity grants to Greenstreet and other executives

The filing

CompanyAlnylam Pharmaceuticals (ALNY)
Form8-K, current report
Filed with the SECMar 4, 2026, 5:17 PM ET
Accession number0001628280-26-014728

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.